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Psychometric validation 
of the needs assessment 
tool: progressive disease in 
interstitial lung disease
ABSTRACT 
The inter-rater/test–retest reliability and 
construct validity of a palliative care needs 
assessment tool in interstitial lung disease 
(NAT:PD-ILD) were tested using NAT:PD-
ILD-guided video-recorded consultations, 
and NAT:PD-ILD-guided consultations, 
and patient and carer-report outcomes (St 
George’s Respiratory Questionnaire (SGRQ)-
ILD, Carer Strain Index (CSI)/Carer Support 
Needs Assessment Tool (CSNAT)). 11/16 items 
reached at least fair inter-rater agreement; 
5 items reached at least moderate test–
retest agreement. 4/6 patient constructs 
demonstrated agreement with SGRQ-I scores 
(Kendall’s tau-b, 0.24–20.36; P<0.05). 4/7 
carer constructs agreed with the CSI/CSNAT 
items (kappa, 0.23–20.53). The NAT:PD-ILD 
is reliable and valid. Clinical effectiveness and 
implementation are to be evaluated.
InTRoduCTIon
People with interstitial lung disease (ILD) 
are symptomatic,1 and have limited 
disease-modifying treatment options, poor 
prognosis and poor quality of life.2 Iden-
tification and management of patients’ 
and carers’ palliative care needs are rare 
despite policy directives promoting palli-
ative care,3 and availability of palliative 
interventions.4 
The validated needs assessment tool 
in cancer (NAT:PD-C) helps clinicians 
identify and address palliative needs in 
daily practice.5 We adapted, validated and 
tested the reliability of the NAT:PD-C 
for patients with ILD (NAT:PD-ILD) 
and explored implementation implica-
tions in practice. This single page guide 
prompts clinicians to assess holistic needs 
(priority prompts for specialised palliative 
care input, patients’ well-being, informal 
carers’ needs and information needs), 
triage ongoing care (‘directly managed’, 
‘refer to other team member’, ‘refer to 
specialist palliative care’) and also acts as 
a referral form.
MeThodS
Summary design
The initial adaptation, face and content 
validation6 and implementation work7 
are reported elsewhere. This study tested 
the psychometric properties of (1) inter-
rater and test–retest reliability, and (2) 
construct validity. 
Clinicians (doctors, nurses, physiother-
apists), patients with ILD and their family 
carers were recruited from four ILD 
tertiary referral clinics.
Inter-rater and test–retest reliability
Video recordings were made of 10 
patient-clinician consultations (range of 
disease severity and carer present/absent, 
with clinicians using the NAT:PD-ILD 
to guide assessment). Clinicians were 
trained to use the NAT:PD-ILD and 
rated at least one video consultation 
(group viewing or individual viewing 
via secure online service). Clinicians 
were asked to rerate the same video 
at least 2 weeks later. Weighted Fleiss’ 
kappa with quadratic weights was calcu-
lated for the ratings on 10 videos (kappa 
<0=poor agreement, 0–0.20=slight, 
0.21–0.40=fair, 0.41–0.60=moderate, 
0.61–0.80=substantial, 0.81–
1=almost perfect agreement).8 Data 
simulations indicated that we required 60 
paired assessment ratings to detect at least 
‘substantial’ inter-rater agreement (kappa 
>0.6) for the item 4 (‘Is the patient expe-
riencing unresolved physical symptoms?’) 
with 80% power.
Construct validation
Trained clinicians conducted a NAT:PD-
ILD-guided clinic consultation. Patients 
completed the St George’s Respiratory 
Questionnaire (SGRQ-I) and carers 
completed the Carer Strain Index (CSI) 
and Carer Support Needs Assessment Tool 
(CSNAT). Kendall’s tau-b correlation 
coefficient was calculated to determine 
the correlation between the NAT:PD-ILD 
patient well-being items and a subset of 
SGRQ-I similar constructs identified a 
priori. The prevalence and bias-adjusted 
kappa (PABAK), Cohen’s kappa and 
observed percentage agreement were 
used to assess agreement between the 
NAT:PD-ILD carer items and appropriate 
CSI and CSNAT constructs identified a 
priori. Data simulations indicated that a 
sample size of 65 patients would allow 
estimation of the kappa statistic for agree-
ment such that the CI would not extend 
beyond the neighbouring category.
All analyses were conducted using Stata 
V.13 (StataCorp, Stata Statistical Soft-
ware: Release 13. College Station, TX: 
StataCorp, 2013).
ReSulTS
Reliability
Fifty-three clinicians (32 doctors, 18 phys-
iotherapists, 2 clinical physiologists, 1 
nurse) participated in 64 first views across 
10 videos, with 21 test–retest observations 
on four videos.
Inter-rater reliability
Eleven (69%) NAT:PD-ILD items 
reached at least fair agreement (weighted 
kappa >0.2).
Test–retest reliability
Five items exhibited at least moderate 
agreement (weighted kappa >0.4) 
(table 1).
Construct validation
Nine clinicians (six doctors, three nurses) 
and 68 patients (mean age 66, SD 10.3; 
62% men; 45 with a carer (28 partici-
pated); 35% oxygen therapy; 56% inter-
stital pulmonary fibrosis ; 80% Medical 
Research Council breathlessness 3–5) were 
recruited (online supplementary eTable 
1). The SGRQ-I mean summary score 
was 62.5 (SD 20.9): symptom component 
67.4 (26.1); activities component 82.1 
(23.2); impact component 51.2 (24.3). 
Scores for the carer comparator outcome 
measures are shown in online supple-
mentary eTable 2. Agreement between 
NAT:PD-ILD concerns and comparator 
outcomes is shown in table 2. Items 2 
(unresolved psychological symptoms/
loss quality of life), 3 (problems with daily 
living activities), 5 (work, financial or legal 
concerns) and 6 (health beliefs, cultural 
or social factors) of the NAT:PD-ILD 
were significantly positively correlated 
with their comparator SGRQ-I scores (r 
range 0.24–0.36, P<0.05). PABAK values 
comparing the NAT:PD-ILD items with 
CSI/CSNAT items were mostly positive 
(0.04–0.57, minimum 52% agreement); 
however, items 11 and 13 have negative 
PABAK values (interpersonal relationships 
and grief topics).
dISCuSSIon
Items within the NAT:PD-ILD demon-
strated acceptable inter-rater reliability 
and construct validation given the broad 
constructs assessed and the breadth of 
clinical experience. The constructs of 
patient-reported quality of life (SGRQ-I) 
and assessment of need are related but 
different, therefore the relatively small 
number of items rated as moderate or 
strong is unsurprising. Similarly, many 
carer-related items both on NAT:PD-ILD 
and within CSI and CSNAT capture 
areas of concern that overlap, but are not 
directly comparable. The NAT-PD-C, with 
similar psychometric properties, resulted 
in reduced patient and carer needs when 
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applied in practice; the key factor in any 
clinical tool.5
The NAT:PD-ILD is best seen as a 
communication and decision tool where 
action is thereby triggered if more 
in-depth exploration is needed, rather 
than an outcome measurement. The 
challenges of a clinical assessment and 
diagnosis are recognised as an inexact 
science with variation between clini-
cians.9 10 Study clinicians had a wide 
range of clinical experience to increase 
generalisability. Some NAT:PD-ILD 
items with poor agreement (inter-rater 
and construct) are consistent with the 
clinician participants’ expressed lack of 
confidence, for example, spiritual and 
existential concerns and may rather 
reflect an educational need.7
The clinician participants rated the 
videos after 10–15 min of training, inter-
rater reliability is likely to improve with 
practice. Clinicians using the tool in daily 
practice will gain more experience as they 
use the tool.
Although we reached our target sample 
size for the construct validity analysis, 
we have insufficient sample for the 
carer comparisons. Also, our sample was 
convenience, not consecutive, potentially 
affecting representativeness.
The tool is yet to be tested in a clin-
ical trial to evaluate its use by clinicians 
in terms of impact on patient and carer 
experience.
ConCluSIonS
The adapted NAT:PD-ILD has adequate 
reliability and construct validation. Effec-
tiveness in clinical practice, and optimum 
implementation are yet to be evaluated 
and identified.
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